"We think ReCell compares well with these products on a cost and effectiveness standpoint, and that confirmation of results seen to date in venous leg ulcer could potentially lead to $50-100 million in peak revenues. In our previous article on Avita focusing on burns and scalds, we suggested that ReCell could have a $200 million peak revenue opportunity in that indication. Approvals in these indications would clearly be an enormous leap forward for this $40 million market capitalization company."
Very nice. even if only make half the prodiction. Say $100mil a year. That should still give us a market cap around $400mil or 10 times the value of where we are at now.
- Forums
- ASX - By Stock
- seekingalpha article on venous ulcers
"We think ReCell compares well with these products on a cost and...
Featured News
Add AVH (ASX) to my watchlist
|
|||||
Last
$3.02 |
Change
0.050(1.68%) |
Mkt cap ! $205.6M |
Open | High | Low | Value | Volume |
$2.97 | $3.04 | $2.97 | $665.9K | 221.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | $3.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.03 | 5341 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 3.020 |
3 | 10267 | 3.010 |
2 | 3045 | 2.960 |
4 | 17116 | 2.950 |
1 | 3000 | 2.920 |
Price($) | Vol. | No. |
---|---|---|
3.030 | 5341 | 3 |
3.040 | 13000 | 3 |
3.050 | 27875 | 4 |
3.080 | 50 | 1 |
3.090 | 12000 | 1 |
Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online